• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌患者的血清和尿液外泌体中存在特定的 RNA 谱,反映了肿瘤的表达:用于疾病诊断的新型液体活检生物标志物。

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis.

机构信息

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014, San Sebastian, Spain.

Biotech Research & Innovation Centre (BRIC), Department of Health and Medical Sciences, 2200, Copenhagen, Denmark.

出版信息

Cells. 2020 Mar 14;9(3):721. doi: 10.3390/cells9030721.

DOI:10.3390/cells9030721
PMID:32183400
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7140677/
Abstract

Cholangiocarcinoma (CCA) comprises a group of heterogeneous biliary cancers with dismal prognosis. The etiologies of most CCAs are unknown, but primary sclerosing cholangitis (PSC) is a risk factor. Non-invasive diagnosis of CCA is challenging and accurate biomarkers are lacking. We aimed to characterize the transcriptomic profile of serum and urine extracellular vesicles (EVs) from patients with CCA, PSC, ulcerative colitis (UC), and healthy individuals. Serum and urine EVs were isolated by serial ultracentrifugations and characterized by nanoparticle tracking analysis, transmission electron microscopy, and immunoblotting. EVs transcriptome was determined by gene expression array [messenger RNAs (mRNA) and non-coding RNAs (ncRNAs)]. Differential RNA profiles were found in serum and urine EVs from patients with CCA compared to control groups (disease and healthy), showing high diagnostic capacity. The comparison of the mRNA profiles of serum or urine EVs from patients with CCA with the transcriptome of tumor tissues from two cohorts of patients, CCA cells in vitro, and CCA cells-derived EVs, identified 105 and 39 commonly-altered transcripts, respectively. Gene ontology analysis indicated that most commonly-altered mRNAs participate in carcinogenic steps. Overall, patients with CCA present specific RNA profiles in EVs mirroring the tumor, and constituting novel promising liquid biopsy biomarkers.

摘要

胆管癌(CCA)是一组具有不良预后的异质性胆道癌。大多数 CCA 的病因尚不清楚,但原发性硬化性胆管炎(PSC)是一个危险因素。CCA 的非侵入性诊断具有挑战性,并且缺乏准确的生物标志物。我们旨在描述 CCA、PSC、溃疡性结肠炎(UC)和健康个体的血清和尿液细胞外囊泡(EV)的转录组特征。通过连续超速离心分离血清和尿液 EV,并通过纳米颗粒跟踪分析、透射电子显微镜和免疫印迹进行表征。通过基因表达阵列[信使 RNA(mRNA)和非编码 RNA(ncRNA)]确定 EV 转录组。与对照组(疾病和健康)相比,CCA 患者的血清和尿液 EV 中的差异 RNA 谱显示出较高的诊断能力。CCA 患者的血清或尿液 EV 的 mRNA 图谱与两个患者队列的肿瘤组织、体外 CCA 细胞和 CCA 细胞衍生的 EV 的转录组进行比较,分别鉴定出 105 个和 39 个常见改变的转录本。基因本体分析表明,大多数常见改变的 mRNAs 参与致癌步骤。总的来说,CCA 患者的 EV 中存在反映肿瘤的特定 RNA 谱,构成了有前途的新型液体活检生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/4939eb877660/cells-09-00721-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/ec7b9fb06c1c/cells-09-00721-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/b65e551c414f/cells-09-00721-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/76a2ba4fd0b2/cells-09-00721-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/a29edd12c4bd/cells-09-00721-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/f10f56076cb2/cells-09-00721-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/1baa2ced6fdb/cells-09-00721-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/04126e925304/cells-09-00721-g007a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/9752f1c842f1/cells-09-00721-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/9acd48d52b56/cells-09-00721-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/4939eb877660/cells-09-00721-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/ec7b9fb06c1c/cells-09-00721-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/b65e551c414f/cells-09-00721-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/76a2ba4fd0b2/cells-09-00721-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/a29edd12c4bd/cells-09-00721-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/f10f56076cb2/cells-09-00721-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/1baa2ced6fdb/cells-09-00721-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/04126e925304/cells-09-00721-g007a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/9752f1c842f1/cells-09-00721-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/9acd48d52b56/cells-09-00721-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4497/7140677/4939eb877660/cells-09-00721-g010.jpg

相似文献

1
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis.胆管癌患者的血清和尿液外泌体中存在特定的 RNA 谱,反映了肿瘤的表达:用于疾病诊断的新型液体活检生物标志物。
Cells. 2020 Mar 14;9(3):721. doi: 10.3390/cells9030721.
2
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.基于液体活检的蛋白生物标志物用于胆管癌的风险预测、早期诊断和预后评估。
J Hepatol. 2023 Jul;79(1):93-108. doi: 10.1016/j.jhep.2023.02.027. Epub 2023 Mar 1.
3
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.血清细胞外囊泡包含原发性硬化性胆管炎和胆管癌的蛋白质生物标志物。
Hepatology. 2017 Oct;66(4):1125-1143. doi: 10.1002/hep.29291. Epub 2017 Aug 26.
4
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis.人胆汁中含有富含 microRNA 的细胞外囊泡,可用于胆管癌的诊断。
Hepatology. 2014 Sep;60(3):896-907. doi: 10.1002/hep.27050. Epub 2014 Jul 25.
5
Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者循环细胞外囊泡的蛋白质和 miRNA 谱。
Sci Rep. 2022 Feb 22;12(1):3027. doi: 10.1038/s41598-022-06809-0.
6
RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma.RNA结合蛋白转录本作为检测原发性硬化性胆管炎及预测其进展为胆管癌的潜在生物标志物。
Front Mol Biosci. 2024 Jun 6;11:1388294. doi: 10.3389/fmolb.2024.1388294. eCollection 2024.
7
Phosphatidylcholine in bile-derived small extracellular vesicles as a novel biomarker of cholangiocarcinoma.胆汁来源的小细胞外囊泡中的磷脂酰胆碱作为胆管癌的新型生物标志物。
Cancer Med. 2023 Jun;12(12):13007-13018. doi: 10.1002/cam4.5973. Epub 2023 Apr 25.
8
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.血清代谢物作为胆管癌、肝细胞癌和原发性硬化性胆管炎的诊断生物标志物。
Hepatology. 2019 Aug;70(2):547-562. doi: 10.1002/hep.30319. Epub 2019 Feb 14.
9
Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma. Claudin-3 在人胆汁外泌体中的应用作为胆管癌生物标志物的研究。
Sci Rep. 2021 Jan 13;11(1):1195. doi: 10.1038/s41598-021-81023-y.
10
Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.胆汁和尿液肽标志物谱:胆管癌分子途径和生物学过程的关键入口。
J Biomed Sci. 2020 Jan 3;27(1):13. doi: 10.1186/s12929-019-0599-5.

引用本文的文献

1
Advancing Cholangiocarcinoma Diagnosis: The Role of Liquid Biopsy and CRISPR/Cas Systems in Biomarker Detection.胆管癌诊断进展:液体活检和CRISPR/Cas系统在生物标志物检测中的作用
Cancers (Basel). 2025 Jun 26;17(13):2155. doi: 10.3390/cancers17132155.
2
Emerging Biomarker Potential of Extracellular Vesicle-Enclosed MicroRNAs for Liver Fibrosis Detection.细胞外囊泡包裹的微小RNA在肝纤维化检测中的新兴生物标志物潜力
Cells. 2025 Jul 4;14(13):1025. doi: 10.3390/cells14131025.
3
Precision oncology in biliary tract cancer: the emerging role of liquid biopsy.

本文引用的文献

1
High expression of NME1 correlates with progression and poor prognosis in patients of hepatocellular carcinoma.NME1的高表达与肝细胞癌患者的病情进展及不良预后相关。
Int J Clin Exp Pathol. 2017 Aug 1;10(8):8561-8568. eCollection 2017.
2
Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.UBE2C 的耗竭通过下调 CDK1 降低卵巢癌恶性程度并逆转顺铂耐药性。
Biochem Biophys Res Commun. 2020 Mar 5;523(2):434-440. doi: 10.1016/j.bbrc.2019.12.058. Epub 2019 Dec 23.
3
UBE2C promotes the progression of head and neck squamous cell carcinoma.
胆道癌的精准肿瘤学:液体活检的新兴作用
ESMO Open. 2025 Apr 30;10(5):105079. doi: 10.1016/j.esmoop.2025.105079.
4
Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy.胆管癌的生物标志物与管理:开启精准治疗的新视野
Cancers (Basel). 2025 Apr 6;17(7):1243. doi: 10.3390/cancers17071243.
5
Cholangiocarcinoma: The era of liquid biopsy.胆管癌:液体活检时代。
World J Gastroenterol. 2025 Mar 21;31(11):104170. doi: 10.3748/wjg.v31.i11.104170.
6
Isolating Astrocyte-Derived Extracellular Vesicles From Urine.从尿液中分离星形胶质细胞衍生的细胞外囊泡。
Int J Nanomedicine. 2025 Feb 26;20:2475-2484. doi: 10.2147/IJN.S492381. eCollection 2025.
7
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance.胆管癌风险、诊断及预后生物标志物的探索及其生物学和临床病理意义
Am J Pathol. 2025 Mar;195(3):422-436. doi: 10.1016/j.ajpath.2024.06.013. Epub 2024 Aug 3.
8
RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma.RNA结合蛋白转录本作为检测原发性硬化性胆管炎及预测其进展为胆管癌的潜在生物标志物。
Front Mol Biosci. 2024 Jun 6;11:1388294. doi: 10.3389/fmolb.2024.1388294. eCollection 2024.
9
The Diagnostic and Prognostic Potentials of Non-Coding RNA in Cholangiocarcinoma.胆管癌中非编码 RNA 的诊断和预后潜力。
Int J Mol Sci. 2024 May 30;25(11):6002. doi: 10.3390/ijms25116002.
10
Clinical significance of small extracellular vesicles in cholangiocarcinoma.小细胞外囊泡在胆管癌中的临床意义
Front Oncol. 2024 Apr 11;14:1334592. doi: 10.3389/fonc.2024.1334592. eCollection 2024.
UBE2C 促进头颈部鳞状细胞癌的进展。
Biochem Biophys Res Commun. 2020 Mar 5;523(2):389-397. doi: 10.1016/j.bbrc.2019.12.064. Epub 2019 Dec 20.
4
CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells.CMIP 促进了 HER2 阳性胃癌细胞对赫赛汀的耐药性。
Pathol Res Pract. 2020 Feb;216(2):152776. doi: 10.1016/j.prp.2019.152776. Epub 2019 Dec 2.
5
Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.沉默泛素连接酶 2C 抑制胰腺导管腺癌的增殖和上皮-间充质转化。
FEBS J. 2019 Dec;286(24):4889-4909. doi: 10.1111/febs.15134. Epub 2019 Nov 29.
6
Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140.长链非编码 RNA MALAT1 通过海绵吸附 miR-140 促进 HCC 细胞的血管生成和免疫抑制特性。
Am J Physiol Cell Physiol. 2020 Mar 1;318(3):C649-C663. doi: 10.1152/ajpcell.00510.2018. Epub 2019 Nov 6.
7
Exosomal MALAT1 derived from hepatic cells is involved in the activation of hepatic stellate cells via miRNA-26b in fibrosis induced by arsenite.砷诱导肝纤维化中细胞外体 MALAT1 通过 miRNA-26b 参与肝星状细胞的激活。
Toxicol Lett. 2019 Nov;316:73-84. doi: 10.1016/j.toxlet.2019.09.008. Epub 2019 Sep 9.
8
Methylation Inactivates Expression of CDP-diacylglycerol Synthase 1 () in Hepatocellular Carcinoma.甲基化使肝细胞癌中CDP-二酰甘油合酶1()的表达失活。
Cancer Genomics Proteomics. 2006 May-Aug;3(3-4):231-238. Epub 2006 Jan 1.
9
Identification of Prognostic Candidate Genes in Breast Cancer by Integrated Bioinformatic Analysis.通过综合生物信息学分析鉴定乳腺癌的预后候选基因
J Clin Med. 2019 Aug 2;8(8):1160. doi: 10.3390/jcm8081160.
10
Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.鉴定一种针对 Notch 驱动的胆管癌的 Pan-Gamma-Secretase 抑制剂反应特征。
Hepatology. 2020 Jan;71(1):196-213. doi: 10.1002/hep.30816. Epub 2019 Aug 19.